955 CORE1: phase 2, single arm study of CG0070 combined with pembrolizumab in patients with non muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG)

• Roger Li,
• Ashish Kamat,
• Gary Steinberg,
• Michael Chisamore,
• James Burke,
• Donald Lamm,
• Ed Uchio,
• Vignesh Packiam,
• John McAdory,
• Paola Grandi,
• Jee-Hyun Kim

Affiliations

Roger Li

Aff646 grid.240145.60000000122914776University of Texas MD Anderson Cancer Center Houston TX USA

Ashish Kamat

Aff646 grid.240145.60000000122914776University of Texas MD Anderson Cancer Center Houston TX USA

Gary Steinberg

Aff1 grid.412578.d0000000087369513University of Chicago Medical Center Chicago IL USA

Michael Chisamore

2Merch and Co., Inc., Rahway, NJ, USA

James Burke

8CG Oncology, Irvine, CA, USA

Donald Lamm

3BCG Oncology, Phoenix, AZ, USA

Ed Uchio

4UCI, Irvinr, CA, USA

Vignesh Packiam

5University of Iowa, Iowa City, IA, USA

John McAdory

8CG Oncology, Irvine, CA, USA

Paola Grandi

8CG Oncology, Irvine, CA, USA

Jee-Hyun Kim

8CG Oncology, Irvine, CA, USA